Balyasny Asset Management’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Balyasny Asset Management’s Portfolio NKGN Stock Details NKGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-310,359	Closed	-$2.58M	–	2986
2023 Q3	$2.58M	Hold	310,359	–	–	0.01%	1314
2023 Q2	$3.21M	Sell	310,359 -389,641	-56%	-$3.99M	0.01%	1216
2023 Q1	$7.09M	Hold	700,000	–	–	0.02%	932
2022 Q4	$6.96M	Buy	700,000 +300,000	+75%	+$2.96M	0.02%	885
2022 Q3	$3.9M	Hold	400,000	–	–	0.01%	1144
2022 Q2	$3.88M	Hold	400,000	–	–	0.01%	1059
2022 Q1	$3.88M	Hold	400,000	–	–	0.01%	1061
2021 Q4	$3.88M	Hold	400,000	–	–	0.01%	936
2021 Q3	$3.88M	Buy	+400,000	New	+$3.9M	0.02%	916

Other funds holding NKGN

SIM

Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return

Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

UOC

University of Chicago Chicago, Illinois $323M AUM 14.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Balyasny Asset Management's NKGN Position: Q4 2023 in Review

Balyasny Asset Management sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q4 2023, closing a stake of 310,359 shares — an estimated $2.58M sold.

Balyasny Asset Management first reported a position in NKGN in Q3 2021 and held it in 9 quarters. The position peaked at $7.09M in Q1 2023. 9 funds tracked by Wall St. Rank hold NKGN as of Q4 2023.

Balyasny Asset Management reported no remaining NKGen Biotech, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Balyasny Asset Management sold 310,359 NKGen Biotech, Inc. Common Stock shares in Q4 2023, an estimated $2.58M.
Balyasny Asset Management first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2021 and held it in 9 quarters.
Balyasny Asset Management's NKGen Biotech, Inc. Common Stock position peaked at $7.09M in Q1 2023.
9 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q4 2023.

Based on Balyasny Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.